Giiant Pharma announced today that it added $1.25 million to its seed financing round to ensure reaching clinical proof-of-concept for its Precision Delivery technology platform. Montreal-based Giiant’s $750,000 in funding from AQC Capital, plus $500,000 from CQDM, adds to the seed round closed last month to bring the company’s total funding to nearly $15 million. […]
Preclinical Trials
MedinCell to begin regulatory development of long-acting injectable malaria treatment
MedinCell announced that its long-acting injectable malaria treatment is ready to enter into the stages of regulatory development. Montpellier, France–based MedinCell conducted an in vivo proof of concept on cattle that demonstrated three-month mosquitocidal effectiveness in the injectable, long-acting formulation of Ivermectin using the company’s BEPO delivery technology. The company designed the investigational mdc-STM product […]
Giiant Pharma raises $11M for drug delivery platform for gastroenterology
Giiant Pharma announced today that it closed a $11 million seed financing round for its drug delivery technology platform. Montreal-based Giiant develops the Precision Delivery technology platform, which originated from the work of former Merck Frosst scientists, according to a news release. The company designs gut-restricted, tissue-specific, small-molecule drug therapeutics to be delivered through the […]
Intravacc touts preclinical, non-human results for COVID-19 nasal spray vaccine
Intravacc is today touting positive pre-clinical results of its SARS-CoV-2 nasal spray vaccine candidate in non-human subjects. Bilthoven, Netherlands-based Intravacc’s SARS-CoV-2 outer membrane vesicle (OMV)-based recombinant spike protein (rSp) nasal spray candidate was observed in four groups of mice and four groups of hamsters, all of which received two intranasal immunizations on day one and […]
Johns Hopkins researchers tout medicine-delivering microdevices
Johns Hopkins researchers are touting microdevices that can latch onto intestinal mucosa and release drugs into the body. Led by engineering professor David Gracias and gastroenterologist Dr. Florin Selaru, the team of researchers and biomedical engineers designed and tested shape-changing microdevices that they say can mimic the way the parasitic hookworm affixes itself to an […]
OncoSec, Inovio testing COVID-19 vaccines
OncoSec Medical (NSDQ:ONCS) and Inovio Pharmaceuticals (NSDQ:INO) announced that they are testing potential COVID-19 vaccines after the latter received investigational new drug clearance from the FDA. Inovio received an IND nod, while OncoSec’s is pending, but both companies are pursuing a first-in-human Phase 1 clinical trial for their vaccines, according to separate news releases. OncoSec is using […]
Rgenix raises $40M to develop novel cancer drugs
Biopharma startup Rgenix said it has raised $40 million in Series C financing to further develop its clinical and pre-clinical oncology programs and for general corporate purposes. New York City-based Rgenix has discovered several novel RNA-regulated cancer targets that drive tumor growth and cancer progression, according to its website. These targets regulate key components of […]
Researchers deliver cardiac stem cell therapy in preclinical trial using refillable patch
Researchers have developed a small device designed to halt the effects of a heart attack by delivering a stem cell therapy directly to damaged cardiac tissue. In a study published in Nature Biomedical Engineering, researchers from Harvard University, the Massachusetts Institute of Technology, the National University of Ireland Galway and Trinity College Dublin reported that the […]
ContraVir’s drug slashes fibrosis by 46% in preclinical study
ContraVir Pharmaceuticals (NSDQ:CTRV) touted encouraging results today from a preclinical study of its cyclophilin inhibitor, CRV431. In an animal model, the drug reduced the extent of fibrosis by 46% compared to the control. The Edison, N.J.-based biopharma company is developing medicines to treat patients who are infected with the hepatitis B virus. In the treatment […]
NanOlogy touts preclinical data for inhaled NanoPac cancer drug
NanOlogy touted results today from preclinical studies of its inhaled submicron particle formulation of paclitaxel, NanoPac. The company said animal studies have shown prolonged retention of the cancer drug in lung tissue and significant tumor regression without adverse drug-related side effects. NanOlogy plans to present the data from its preclinical studies at this year’s annual […]
